Unlocking the unmatched potential
for timed immunotherapeutics
to combat disease

Unlocking the unmatched
potential for timed
immunotherapeutics
to combat disease

I AM INTERESTED IN

HUMAN TRIALS

VETERINARY TRIALS

Break-Through Invention for Treating Cancer

Biotempus is unlocking the unmatched potential for timed immunotherapeutics to combat disease. We have developed a deep insight into how drug efficacy can be increased and toxicity reduced by synchronising treatments in accordance with cycles within the immune system.

About Biotempus

Biotempus Limited is the successor to ImmunAid Pty Ltd, previously majority owned by Genetic Technologies Limited. Biotempus is based in Melbourne, Australia and now operates as a independent company developing and commercialising technologies for leveraging immune system responses against disease.

Technology

Modern drugs have reduced the toxicity of many treatments but have not significantly improved complete responses. This, we believe, is not due to fundamental problems with the agents themselves. Rather, it is due to the random timing of their application. Drug treatments are at present scheduled according to a range of clinical and non-clinical considerations but not with regard to what Biotempus has identified as the most important factor: the dynamics of the individual patient’s immune system.

Help us Cure Cancer in Dogs

Join the breakthrough trial! Synchronisation of Immunotherapy – Using Serial C-Reactive Protein (CRP) Measurements in Dogs.
We are looking for 20 leading clinics around Australia to take part in this study. We will be making contact with selected clinics to schedule further training and installation of the CRP point of care instrument.